530 related articles for article (PubMed ID: 12506174)
1. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV.
Breneman JC; Lyden E; Pappo AS; Link MP; Anderson JR; Parham DM; Qualman SJ; Wharam MD; Donaldson SS; Maurer HM; Meyer WH; Baker KS; Paidas CN; Crist WM
J Clin Oncol; 2003 Jan; 21(1):78-84. PubMed ID: 12506174
[TBL] [Abstract][Full Text] [Related]
2. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease.
Crist WM; Anderson JR; Meza JL; Fryer C; Raney RB; Ruymann FB; Breneman J; Qualman SJ; Wiener E; Wharam M; Lobe T; Webber B; Maurer HM; Donaldson SS
J Clin Oncol; 2001 Jun; 19(12):3091-102. PubMed ID: 11408506
[TBL] [Abstract][Full Text] [Related]
3. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.
Meza JL; Anderson J; Pappo AS; Meyer WH;
J Clin Oncol; 2006 Aug; 24(24):3844-51. PubMed ID: 16921036
[TBL] [Abstract][Full Text] [Related]
4. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
Breitfeld PP; Lyden E; Raney RB; Teot LA; Wharam M; Lobe T; Crist WM; Maurer HM; Donaldson SS; Ruymann FB
J Pediatr Hematol Oncol; 2001 May; 23(4):225-33. PubMed ID: 11846301
[TBL] [Abstract][Full Text] [Related]
5. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV.
Baker KS; Anderson JR; Link MP; Grier HE; Qualman SJ; Maurer HM; Breneman JC; Wiener ES; Crist WM
J Clin Oncol; 2000 Jun; 18(12):2427-34. PubMed ID: 10856103
[TBL] [Abstract][Full Text] [Related]
6. The Third Intergroup Rhabdomyosarcoma Study.
Crist W; Gehan EA; Ragab AH; Dickman PS; Donaldson SS; Fryer C; Hammond D; Hays DM; Herrmann J; Heyn R
J Clin Oncol; 1995 Mar; 13(3):610-30. PubMed ID: 7884423
[TBL] [Abstract][Full Text] [Related]
7. Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.
Arndt CA; Hawkins DS; Meyer WH; Sencer SF; Neglia JP; Anderson JR
Pediatr Blood Cancer; 2008 Jan; 50(1):33-6. PubMed ID: 17091486
[TBL] [Abstract][Full Text] [Related]
8. Improved outcome for patients with middle ear rhabdomyosarcoma: a children's oncology group study.
Hawkins DS; Anderson JR; Paidas CN; Wharam MD; Qualman SJ; Pappo AS; Scott Baker K; Crist WM
J Clin Oncol; 2001 Jun; 19(12):3073-9. PubMed ID: 11408504
[TBL] [Abstract][Full Text] [Related]
9. Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
; Lager JJ; Lyden ER; Anderson JR; Pappo AS; Meyer WH; Breitfeld PP
J Clin Oncol; 2006 Jul; 24(21):3415-22. PubMed ID: 16849756
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors and surgical treatment guidelines for children with rhabdomyosarcoma of the perineum or anus: a report of Intergroup Rhabdomyosarcoma Studies I through IV, 1972 through 1997.
Blakely ML; Andrassy RJ; Raney RB; Anderson JR; Wiener ES; Rodeberg DA; Paidas CN; Lobe TE; Crist WM;
J Pediatr Surg; 2003 Mar; 38(3):347-53. PubMed ID: 12632347
[TBL] [Abstract][Full Text] [Related]
11. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.
Raney RB; Anderson JR; Barr FG; Donaldson SS; Pappo AS; Qualman SJ; Wiener ES; Maurer HM; Crist WM
J Pediatr Hematol Oncol; 2001 May; 23(4):215-20. PubMed ID: 11846299
[TBL] [Abstract][Full Text] [Related]
12. Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Studies I to III.
Wolden SL; Anderson JR; Crist WM; Breneman JC; Wharam MD; Wiener ES; Qualman SJ; Donaldson SS
J Clin Oncol; 1999 Nov; 17(11):3468-75. PubMed ID: 10550144
[TBL] [Abstract][Full Text] [Related]
13. Treatment of localized nonorbital, nonparameningeal head and neck rhabdomyosarcoma: lessons learned from intergroup rhabdomyosarcoma studies III and IV.
Pappo AS; Meza JL; Donaldson SS; Wharam MD; Wiener ES; Qualman SJ; Maurer HM; Crist WM
J Clin Oncol; 2003 Feb; 21(4):638-45. PubMed ID: 12586800
[TBL] [Abstract][Full Text] [Related]
14. European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors.
Carli M; Colombatti R; Oberlin O; Bisogno G; Treuner J; Koscielniak E; Tridello G; Garaventa A; Pinkerton R; Stevens M
J Clin Oncol; 2004 Dec; 22(23):4787-94. PubMed ID: 15570080
[TBL] [Abstract][Full Text] [Related]
15. Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the soft tissue sarcoma committee of the children's oncology group.
Smith LM; Anderson JR; Qualman SJ; Crist WM; Paidas CN; Teot LA; Pappo AS; Link MP; Grier HE; Wiener ES; Breneman JC; Raney RB; Maurer HM; Donaldson SS
J Clin Oncol; 2001 Oct; 19(20):4058-64. PubMed ID: 11600608
[TBL] [Abstract][Full Text] [Related]
16. Outcome for children with group III rhabdomyosarcoma treated with or without radiotherapy.
Viswanathan AN; Grier HE; Litman HJ; Perez-Atayde A; Tarbell NJ; Neuberg D; Shamberger RC; Marcus KJ
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1208-14. PubMed ID: 15001265
[TBL] [Abstract][Full Text] [Related]
17. The Intergroup Rhabdomyosarcoma Study-II.
Maurer HM; Gehan EA; Beltangady M; Crist W; Dickman PS; Donaldson SS; Fryer C; Hammond D; Hays DM; Herrmann J
Cancer; 1993 Mar; 71(5):1904-22. PubMed ID: 8448756
[TBL] [Abstract][Full Text] [Related]
18. [Clinical and prognostic analysis of single-center multidisciplinary treatment for rhabdomyosarcoma in children].
Xu N; Duan C; Jin M; Zhang DW; Su Y; Yu T; He LJ; Fu LB; Zeng Q; Wang HM; Zhang WP; Ni X; Ma XL
Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):767-773. PubMed ID: 31594063
[No Abstract] [Full Text] [Related]
19. Results in patients with cranial parameningeal sarcoma and metastases (Stage 4) treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols II-IV, 1978-1997: report from the Children's Oncology Group.
Raney B; Anderson J; Breneman J; Donaldson SS; Huh W; Maurer H; Michalski J; Qualman S; Ullrich F; Wharam M; Meyer W;
Pediatr Blood Cancer; 2008 Jul; 51(1):17-22. PubMed ID: 18266224
[TBL] [Abstract][Full Text] [Related]
20. Prognosis in children with rhabdomyosarcoma: a report of the intergroup rhabdomyosarcoma studies I and II. Intergroup Rhabdomyosarcoma Committee.
Crist WM; Garnsey L; Beltangady MS; Gehan E; Ruymann F; Webber B; Hays DM; Wharam M; Maurer HM
J Clin Oncol; 1990 Mar; 8(3):443-52. PubMed ID: 2407808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
